Corcept Therapeutics

CORT | NASDAQ

Price Alert Chart Builder DCF Calculator

$80.47

-$0.65 (-0.80%)

Nov 2, 2026, 3:40 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.80%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

59.7

+16.0 pts

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Sector Rank #136/1028 (Top 13%)

Full Analysis

Key Statistics

Market Data

Market Cap $8.7B

1D Range

79.43 82.23

52W Range

32.15 123.57

Valuation (TTM)

PE 193.07

PB 12.42

EV/EBITDA 294.10

Valuation (NTM)

Forward PE 20.00

Forward PEG 1.38

Price Target $125.33

Cash Flow

FCF Yield 1.2%

SBC Adj. FCF Yield 1.4%

SBC Impact -10.5%

Margins

Gross Margin 98.3%

Operating Margin 0.8%

FCF Margin 12.9%

Growth (CAGR)

Revenue 3Y | 5Y 24.7% | 19.4%

Dil EPS 3Y | 5Y -20.3% | -11.2%

FCF 3Y | 5Y -7.4% | -4.4%

Returns

ROA 6.2%

ROE 8.4%

ROIC 0.9%

Financial Health

Net Cash

$298.78M

Current Ratio 2.86

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments fo...

Sector Healthcare

Industry Medical - Pharmaceuticals

Employees 730

IPO Date Apr 14, 2004

Website www.corcept.com

Fiscal Year January - December

Full Company Profile

Latest News

14 days ago · zacks.com

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.

1 month ago · businesswire.com

Corcept Announces Planned Leadership Transition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company's Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October.

1 month ago · zacks.com

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

2 months ago · businesswire.com

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.

2 months ago · zacks.com

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.

2 months ago · fxempire.com

Corcept Grows to Mid-Cap on Institutional Support

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.

2 months ago · seekingalpha.com

Corcept: Not Cheap, But Backed By Real Structural Growth

Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.

2 months ago · zacks.com

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

Like The Knick's, Corcept Rebounded And Is Crushing It

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.